{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:02:37Z","timestamp":1791417757205,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-024-02496-0","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:16:25Z","timestamp":1734956185000},"page":"663-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis"],"prefix":"10.1038","volume":"39","author":[{"given":"Shivani","family":"Handa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-4858","authenticated-orcid":false,"given":"Christoph","family":"Schaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-1081","authenticated-orcid":false,"given":"Joseph","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiva","family":"Ahire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-9310","authenticated-orcid":false,"given":"Md. Babu","family":"Mia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Klingborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Marcellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6732","authenticated-orcid":false,"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-7722","authenticated-orcid":false,"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2496_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergencyto.2007.05.009","volume":"177","author":"S Aliano","year":"2007","unstructured":"Aliano S, Cirmena G, Garuti A, Fugazza G, Bruzzone R, Rocco I, et al. HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22). Cancer Genet Cytogenet. 2007;177:115\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"2496_CR2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.10297","volume":"39","author":"J Andrieux","year":"2004","unstructured":"Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer. 2004;39:82\u20137.","journal-title":"Genes Chromosomes Cancer"},{"key":"2496_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cancergencyto.2007.03.009","volume":"176","author":"A Etienne","year":"2007","unstructured":"Etienne A, Carbuccia N, Adelaide J, Bekhouche I, Remy V, Sohn C, et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet. 2007;176:80\u201388.","journal-title":"Cancer Genet Cytogenet"},{"key":"2496_CR4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cancergen.2012.03.006","volume":"205","author":"SE Martin","year":"2012","unstructured":"Martin SE, Sausen M, Joseph A, Kingham BF, Martin ES. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm. Cancer Genet. 2012;205:295\u2013303.","journal-title":"Cancer Genet"},{"key":"2496_CR5","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2404418","volume":"20","author":"CT Storlazzi","year":"2006","unstructured":"Storlazzi CT, Albano F, Locunsolo C, Lonoce A, Funes S, Guastadisegni MC, et al. t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene. Leukemia. 2006;20:2190\u20132.","journal-title":"Leukemia"},{"key":"2496_CR6","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","volume":"117","author":"K Ikeda","year":"2011","unstructured":"Ikeda K, Mason PJ, Bessler M. 3\u2019UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011;117:5860\u20139.","journal-title":"Blood"},{"key":"2496_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5387\/fms.58.91","volume":"58","author":"K Ikeda","year":"2012","unstructured":"Ikeda K, Ogawa K, Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. Fukushima J Med Sci. 2012;58:91\u2013100.","journal-title":"Fukushima J Med Sci"},{"key":"2496_CR8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjh.13129","volume":"168","author":"K Harada-Shirado","year":"2015","unstructured":"Harada-Shirado K, Ikeda K, Ogawa K, Ohkawara H, Kimura H, Kai T, et al. Dysregulation of the MIRLET7\/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br J Haematol. 2015;168:338\u201349.","journal-title":"Br J Haematol"},{"key":"2496_CR9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3324\/haematol.2016.154385","volume":"102","author":"CC Chen","year":"2017","unstructured":"Chen CC, You JY, Lung J, Huang CE, Chen YY, Leu YW, et al. Aberrant let7a\/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica. 2017;102:509\u201318.","journal-title":"Haematologica"},{"key":"2496_CR10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2017004457","volume":"1","author":"K Ueda","year":"2017","unstructured":"Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, et al. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv. 2017;1:1001\u201315.","journal-title":"Blood Adv"},{"key":"2496_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.leu.2403605","volume":"19","author":"MD Odero","year":"2005","unstructured":"Odero MD, Grand FH, Iqbal S, Ross F, Roman JP, Vizmanos JL, et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia. 2005;19:245\u201352.","journal-title":"Leukemia"},{"key":"2496_CR12","first-page":"289","volume":"32","author":"I Cleynen","year":"2008","unstructured":"Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol. 2008;32:289\u2013305.","journal-title":"Int J Oncol"},{"key":"2496_CR13","doi-asserted-by":"crossref","unstructured":"Battista S, Fedele M, Secco L, Ingo AMD, Sgarra R, Manfioletti G. Binding to the other side: the AT-Hook DNA-binding domain allows nuclear factors to exploit the DNA minor groove. Int J Mol Sci. 2024;25:8863.","DOI":"10.3390\/ijms25168863"},{"key":"2496_CR14","doi-asserted-by":"crossref","unstructured":"Parisi S, Piscitelli S, Passaro F, Russo T. HMGA proteins in stemness and differentiation of embryonic and adult stem cells. Int J Mol Sci. 2020;21:362.","DOI":"10.3390\/ijms21010362"},{"key":"2496_CR15","doi-asserted-by":"crossref","unstructured":"Vignali R, Marracci S. HMGA genes and proteins in development and evolution. Int J Mol Sci. 2020;21:654.","DOI":"10.3390\/ijms21020654"},{"key":"2496_CR16","doi-asserted-by":"crossref","unstructured":"Mansoori B, Mohammadi A, Ditzel HJ, Duijf PHG, Khaze V, Gjerstorff MF, et al. HMGA2 as a critical regulator in cancer development. Genes. 2021;12:269.","DOI":"10.3390\/genes12020269"},{"key":"2496_CR17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12672-024-01202-x","volume":"15","author":"F Khazem","year":"2024","unstructured":"Khazem F, Zetoune AB. Decoding high mobility group A2 protein expression regulation and implications in human cancers. Discov Oncol. 2024;15:322.","journal-title":"Discov Oncol"},{"key":"2496_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0092-8674(95)90052-7","volume":"82","author":"HR Ashar","year":"1995","unstructured":"Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell. 1995;82:57\u201365.","journal-title":"Cell"},{"key":"2496_CR19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng0895-436","volume":"10","author":"EF Schoenmakers","year":"1995","unstructured":"Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 1995;10:436\u201344.","journal-title":"Nat Genet"},{"key":"2496_CR20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1101\/gad.1540407","volume":"21","author":"YS Lee","year":"2007","unstructured":"Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025\u201330.","journal-title":"Genes Dev"},{"key":"2496_CR21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.biocel.2009.02.023","volume":"42","author":"MA Newman","year":"2010","unstructured":"Newman MA, Hammond SM. Lin-28: an early embryonic sentinel that blocks Let-7 biogenesis. Int J Biochem Cell Biol. 2010;42:1330\u20133.","journal-title":"Int J Biochem Cell Biol"},{"key":"2496_CR22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1101\/gad.415007","volume":"21","author":"A Polesskaya","year":"2007","unstructured":"Polesskaya A, Cuvellier S, Naguibneva I, Duquet A, Moss EG, Harel-Bellan A. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev. 2007;21:1125\u201338.","journal-title":"Genes Dev"},{"key":"2496_CR23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","volume":"41","author":"SR Viswanathan","year":"2009","unstructured":"Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843\u20138.","journal-title":"Nat Genet"},{"key":"2496_CR24","doi-asserted-by":"crossref","first-page":"17386","DOI":"10.1074\/jbc.M111.321158","volume":"287","author":"N Li","year":"2012","unstructured":"Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, et al. Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem. 2012;287:17386\u201397.","journal-title":"J Biol Chem"},{"key":"2496_CR25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.18632\/oncotarget.785","volume":"3","author":"NM Alajez","year":"2012","unstructured":"Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget. 2012;3:1641\u201352.","journal-title":"Oncotarget"},{"key":"2496_CR26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2012-12-472308","volume":"122","author":"YT Lee","year":"2013","unstructured":"Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood. 2013;122:1034\u201341.","journal-title":"Blood"},{"key":"2496_CR27","doi-asserted-by":"crossref","first-page":"e106924","DOI":"10.1371\/journal.pone.0106924","volume":"9","author":"JF de Vasconcellos","year":"2014","unstructured":"de Vasconcellos JF, Fasano RM, Lee YT, Kaushal M, Byrnes C, Meier ER, et al. LIN28A expression reduces sickling of cultured human erythrocytes. PLoS ONE. 2014;9:e106924.","journal-title":"PLoS ONE"},{"key":"2496_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fgene.2017.00031","volume":"8","author":"J Balzeau","year":"2017","unstructured":"Balzeau J, Menezes MR, Cao S, Hagan JP. The LIN28\/let-7 pathway in cancer. Front Genet. 2017;8:31.","journal-title":"Front Genet"},{"key":"2496_CR29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2016-12-757344","volume":"130","author":"A Dutta","year":"2017","unstructured":"Dutta A, Hutchison RE, Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2(V617F) knockin mice by enhancing TGF-beta1 and Cxcl12 pathways. Blood. 2017;130:920\u201332.","journal-title":"Blood"},{"key":"2496_CR30","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2496_CR31","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Hastings RJ, More S. ISCN 2020: An International System for Human Cytogenomic Nomenclature. Karger AG; 2020.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"2496_CR32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2002.03763.x","volume":"119","author":"V Najfeld","year":"2002","unstructured":"Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol. 2002;119:558\u201366.","journal-title":"Br J Haematol"},{"key":"2496_CR33","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2018.193763","volume":"103","author":"E Zimran","year":"2018","unstructured":"Zimran E, Tripodi J, Rampal R, Rappoport F, Zirkiev S, Hoffman R, et al. Genomic characterization of spleens in patients with myelofibrosis. Haematologica. 2018;103:e446\u20139.","journal-title":"Haematologica"},{"key":"2496_CR34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","volume":"78","author":"B Psaila","year":"2020","unstructured":"Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell. 2020;78:477\u2013492.e478.","journal-title":"Mol Cell"},{"key":"2496_CR35","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood.2021013925","volume":"139","author":"L Li","year":"2022","unstructured":"Li L, Kim JH, Lu W, Williams DM, Kim J, Cope L, et al. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022;139:2797\u2013815.","journal-title":"Blood"},{"key":"2496_CR36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"2496_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.leukres.2015.01.012","volume":"39","author":"CB Benton","year":"2015","unstructured":"Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, et al. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015;39:419\u201323.","journal-title":"Leuk Res"},{"key":"2496_CR38","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","volume":"2","author":"BK Marcellino","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018;2:3581\u20139.","journal-title":"Blood Adv"},{"key":"2496_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","volume":"25","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1). Stem Cells. 2007;25:165\u201373.","journal-title":"Stem Cells"},{"key":"2496_CR40","doi-asserted-by":"crossref","unstructured":"Erdos K, Lee N, Lebbe A, Bouhali I, Khalid M, Abu-Zeinah G, et al. Low thrombosis risk CALR mutations confer higher risk of essential thrombocythemia progression. Blood 2023;142:1819.","DOI":"10.1182\/blood-2023-188952"},{"key":"2496_CR41","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 2021;96:1472\u201380.","journal-title":"Am J Hematol"},{"key":"2496_CR42","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","volume":"127","author":"Y Yang","year":"2016","unstructured":"Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410\u201323.","journal-title":"Blood"},{"key":"2496_CR43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","volume":"213","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213:1479\u201396.","journal-title":"J Exp Med"},{"key":"2496_CR44","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","volume":"213","author":"G Sashida","year":"2016","unstructured":"Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213:1459\u201377.","journal-title":"J Exp Med"},{"key":"2496_CR45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","volume":"22","author":"NP Blackledge","year":"2021","unstructured":"Blackledge NP, Klose RJ. The molecular principles of gene regulation by Polycomb repressive complexes. Nat Rev Mol Cell Biol. 2021;22:815\u201333.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2496_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/BST20230336","volume":"52","author":"S Ito","year":"2024","unstructured":"Ito S, Umehara T, Koseki H. Polycomb-mediated histone modifications and gene regulation. Biochem Soc Trans. 2024;52:151\u201361.","journal-title":"Biochem Soc Trans"},{"key":"2496_CR47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00277-020-04387-7","volume":"100","author":"Z Wang","year":"2021","unstructured":"Wang Z, Liu W, Wang M, Li Y, Wang X, Yang E, et al. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. Ann Hematol. 2021;100:465\u201379.","journal-title":"Ann Hematol"},{"key":"2496_CR48","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","volume":"5","author":"D Luque Paz","year":"2021","unstructured":"Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto JC, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5:1442\u201351.","journal-title":"Blood Adv"},{"key":"2496_CR49","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","volume":"126","author":"L Masarova","year":"2020","unstructured":"Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, et al. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020;126:4322\u201331.","journal-title":"Cancer"},{"key":"2496_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0103-6","volume":"8","author":"M Marquis","year":"2018","unstructured":"Marquis M, Beaubois C, Lavallee VP, Abrahamowicz M, Danieli C, Lemieux S, et al. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018;8:68.","journal-title":"Blood Cancer J"},{"key":"2496_CR51","first-page":"427","volume":"44","author":"S Yang","year":"2019","unstructured":"Yang S, Gu Y, Wang G, Hu Q, Chen S, Wang Y, et al. HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt\/beta-catenin signaling. Int J Mol Med. 2019;44:427\u201336.","journal-title":"Int J Mol Med"},{"key":"2496_CR52","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1182\/bloodadvances.2021005828","volume":"6","author":"C Moison","year":"2022","unstructured":"Moison C, Spinella JF, Chagraoui J, Lavallee VP, Lehnertz B, Thiollier C, et al. HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2\/M inhibition. Blood Adv. 2022;6:4793\u2013806.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02496-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:09:45Z","timestamp":1741104585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02496-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board (IRB study number: 22-00852) and research was conducted in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. Given the retrospective nature of this analysis, informed consent was not required by local regulatory authorities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}